Clinical Research studies

These enrolling research studies are for patients with newly diagnosed AML.

We differentiate the clinical trials according to the patient group they aim to include, from CML to fit, unfit and, residual AML.

CML

Behandling av kronisk tretthet ved blodkreft

Pasienter med kronisk myelogen leukemi behandles med kinasehemmere, en tablettbehandling som resulterer i forventet overlevelse som friske. Samtidig rapporterer mange pasienter, særlig yngre kvinner, alvorlig kronisk tretthet (fatigue) og kognitive vansker som rammer arbeid, studier og familieliv. Denne studien vil undersøke klinisk intervensjon i tre pasientgrupper:

  • KML pasienter som har fått/gjennomgått TKI-behandling i minst 3 måneder.
  • pasienter med myeloproliferativ neoplasi (MPN) uten behandling.
  • pasienter med MPN som har gjennomgått allogen hematopoietisk stamcellebehandling for 6-9 måneder siden.

Les mer om studien her.

FIT AML

HOVON 501

Intensive chemotherapy in combination with venetoclax/placebo.

Unknown starting time

Sites: Oslo universitetssykehus, Haukeland universitetssjukehus, Stavanger universitetssjukehus,  Universitetssjukehuset i Nord Norge, Sankt Olavs Hospital HOVON site

Quantum-wild

For FLT3-ITD negative patients in combination with intensive chemotherapy and as maintenance.

Starting Winter 2024/2025

Sites: UNN, OUS Onc Live ASH publication ClinicalTrials.gov

Un FIT AML

Huvamer

Repurposing in personalized leukemia therapy

Hydroxyurea + Valproat vs. 6-mercaptopurine + Valproat: newly diagnosted AML patients, not candidates for standard intensive treatment  R/R AML, high risk MDS

Start time: ongoing

Sites: Haukeland universitetssjukehus, Bjørn Tore Gjertsen The Research Council of Norway CTV Helse Bergen information

QC+VPA

Quinacrine;Mepacrine + Valproic acid; Orfiril Long depot caps.) off- label treatment outside a clinical study.

 R/R AML patients with chronic infections unfit for other available treatment.

Start time: ongoing

Sites: Haukeland universitetssjukehus, Bjørn Tore Gjertsen

Residual disease AML

IMPRESS
  1. IMPRESS: early KMML/AML, MDS and AML high risk genetics
  2. IMPRESS AML MELFALAN: including AML/MDS with low to normal ( up to 50%) cellularity,  excluding patients with more than two cytogenetic aberrations or chromosome 7 aberrations, TP52 >20%.
  3. IMPRESS AML ACTINOMYCIN D  Including NPM1 mutated AML/high risk MDS, exluding FLT3 mutation

 

sites: Haukeland universitetssjukehus, Bjørn Tore Gjertsen, XX Emil Nyquist. The Research Council of Norway